Please assess the completion status of the following clinical trial:

Trial Title: Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female renal recipients 18-75 years of age undergoing kidney transplantation, from a primary deceased donor (including expanded criteria donor organs), living unrelated or non-HLA identical living related donor kidney;~* Recipient of a kidney with a cold ischemia time \< 30 hours;~* Graft must be functional (producing greater than or equal to 300 ml of urine within 24 hours after transplantation) at time of randomization.~Exclusion Criteria:~* Donor organ with a cold ischemic time \> 30 hours;~* Patients who produce less than 300 ml of urine in the first 24 hours post-transplantation;~* Patients who are recipients of multiple organ transplants;~* Patients who are recipients of ABO incompatible transplants, or T or B cell cross match positive transplant;~* Patients with current Panel Reactive Antibodies (PRA) level ≥ 50%;~* Patients with severe hypercholesterolemia (350 mg/dl) or hypertriglyceridemia (500 mg/dl). Patients on lipid lowering treatment with controlled hyperlipidemia are acceptable;~* HIV positive patients;~* Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception;~* Decisional impaired subjects who are not medically or mentally capable of providing consent themselves.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Mycophenolate + Low Tacrolimus (Type: ACTIVE_COMPARATOR): Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1. Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.~Steroids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg).
- Everolimus + Very Low Tacrolimus (Type: EXPERIMENTAL): Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.~Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.~Corticoids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).